Repligen Corporation
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Repligen Corporation now
Current reporting with the operating signal separated from the noise.
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Investors are testing whether Repligen Corporation’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Repligen Corporation to Acquire BioLife Solutions for $1.5 Billion, Boosting Cell Therapy Market Presence
The story matters when it changes Repligen Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Repligen Corporation Acquires Desktop Bioprocessing Devices from 908 Devices Inc. for $70 Million
The story matters when it changes Repligen Corporation’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Earnings Beat: Repligen Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Investors are testing whether Repligen Corporation’s operating performance supports its strategy and valuation.
Watch next: official volume, pricing, inventory and segment margin.Latest RGEN filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Repligen Corporation, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →